ClinicalTrials.gg
CompletedNCT04985942Updated May 2, 2025Results posted

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Phase 3 interventional study of Lumateperone and Placebo in Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 54 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
13th of 52
485 · median 203
Started
2021
with 5 others
Phase 3
23 of 59
5 open now
Registered
43rd of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 13th largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 in phase 3, and was the 43rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Read the detailed description

The study will be conducted in three periods:

  • Screening Period (up to 2 weeks) during which patient eligibility will be assessed;
  • Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42mg/day in 1:1 ratio.
  • Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Adjunctive MDD Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients between the ages of 18 and 65 years, inclusive;
  2. Meet diagnostic criteria for MDD (a diagnosis of MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the Mini-International Neuropsychiatric Interview (MINI), and meet all the following criteria:

    1. The start of the current major depressive episode (MDE) is at least 8 weeks but not more than 18 months prior to Screening;
    2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
    3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
    4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥14 at Screening and at Baseline;
    5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing distress or impairment in social, occupational, or other important areas of functioning.
  3. Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:

    1. citalopram/escitalopram
    2. fluoxetine
    3. paroxetine
    4. sertraline
    5. duloxetine
    6. levomilnacipran/milnacipran (if locally approved for MDD)
    7. venlafaxine/desvenlafaxine
    8. buproprion
    9. vilazodone
    10. vortioxetine

Exclusion criteria

Exclusion Criteria:

  1. Within the patient's lifetime, has a confirmed psychiatric diagnosis other than MDD, including:

    1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
    2. Bipolar Disorder;
  2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:

    1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses.
    2. Eating disorder;
    3. Substance use disorders (excluding nicotine);
    4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
    5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
  3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
  4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
  5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:

    1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
    2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
    3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
    4. The patient is considered to be in imminent danger to him/herself or others.
  6. The patient has a first MDE at age 60 years or older.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg

    Drug: Lumateperone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lumateperone 42 mg capsules administered orally, once daily.

  • DrugPlacebo

    Matching capsules administered orally, once daily.

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale

    Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Day 43

Secondary outcomes

  1. Clinical Global Impression Scale-Severity

    Change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S). The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Day 43

07

Results

Posted May 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 42 mgPlacebo
Started241243
Completed220232
Not completed2111
Withdrew: Adverse event142
Withdrew: Lack of efficacy03
Withdrew: Lost to follow-up11
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject54

Outcome measures

PrimaryMontgomery-Åsberg Depression Rating Scale

Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Montgomery-Åsberg Depression Rating Scale
score on a scaleLumateperone 42 mgPlacebo
Montgomery-Åsberg Depression Rating Scale-14.7 ± 0.54-9.8 ± 0.53
Statistical analysis
  • Lumateperone 42 mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -4.9 · 95% CI -6.38 to -3.44MMRM Analysis Based on Hypothetical Estimand Strategy
SecondaryClinical Global Impression Scale-Severity

Change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S). The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Clinical Global Impression Scale-Severity
score on a scaleLumateperone 42 mgPlacebo
Clinical Global Impression Scale-Severity-1.6 ± 0.07-0.9 ± 0.07
Statistical analysis
  • Lumateperone 42 mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -0.7 · 95% CI -0.85 to -0.48MMRM Analysis Based on Hypothetical Estimand Strategy

Adverse events

Collected over From signing ICF until end of study procedures (~9 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42 mg0/241 (0%)1/241 (0.4%)92/241 (38.2%)
Placebo0/243 (0%)1/243 (0.4%)53/243 (21.8%)
Most frequent serious events
Most frequent serious events
EventLumateperone 42 mgPlacebo
DepressionPsychiatric disorders1/2410/243
Joint dislocationInjury, poisoning and procedural complications0/2411/243
Most frequent other events
Most frequent other events
EventLumateperone 42 mgPlacebo
HeadacheNervous system disorders38/24137/243
Dry MouthGastrointestinal disorders26/2415/243
DizzinessNervous system disorders25/24115/243
FatigueGeneral disorders23/2415/243
TremorNervous system disorders12/2411/243
NauseaGastrointestinal disorders12/24110/243

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 42 mgPlaceboTotal
Mean45.0 ± 12.3945.1 ± 12.5145.0 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42 mgPlaceboTotal
Female158160318
Male8383166
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 42 mgPlaceboTotal
White180191371
Asian403373
Black or African American201636
Other134
Region of Enrollment
Region of Enrollment(participants)Lumateperone 42 mgPlaceboTotal
Hungary61016
United States7575150
Czechia5154105
Slovakia211839
Bulgaria5455109
India343165
Montgomery Asberg Depression Rating Scale (MADRS)
Montgomery Asberg Depression Rating Scale (MADRS)(units on a scale)Lumateperone 42 mgPlaceboTotal
Mean30.4 ± 3.7630.0 ± 3.5130.2 ± 3.64
08

Study locations

54 sites
  • Clinical Site
    Phoenix, Arizona 85012, United States
  • Clinical Site
    Glendale, California 91206, United States
  • Clinical Site
    Oceanside, California 92056, United States
  • Clinical Site
    Redlands, California 92374, United States
  • Clinical Site
    Temecula, California 92591, United States
  • Clinical Site
    Upland, California 91786, United States
  • Clinical Site
    Fort Lauderdale, Florida 33319, United States
  • Clinical Site
    Jacksonville, Florida 32256, United States
  • Clinical Site
    Orlando, Florida 32801, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    Boston, Massachusetts 02131, United States
  • Clinical Site
    Berlin, New Jersey 08009, United States
  • Clinical Site
    Toms River, New Jersey 08755, United States
  • Clinical Site
    Cedarhurst, New York 11516, United States
  • Clinical Site
    Austin, Texas 78737, United States
  • Clinical Site
    Burgas, 8001, Bulgaria
  • Clinical Site
    Kazanlak, 6100, Bulgaria
  • Clinical Site
    Pleven, 5809, Bulgaria
  • Clinical Site
    Ruse, 7003, Bulgaria
  • Clinical Site
    Tsarev Brod, 9747, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5047, Bulgaria
  • Clinical Site
    Vratsa, 3001, Bulgaria
  • Clinical Site
    Brno, 60200, Czechia
  • Clinical Site
    Brno, 615 000, Czechia
  • Clinical Site
    Ostrava, 70800, Czechia
  • Clinical site
    Plzen, 301 00, Czechia
  • Clinical Site
    Prague, 160 00, Czechia
  • Clinical Site
    Prague, 186 00, Czechia
  • Clinical Site
    Budapest, 1033, Hungary
  • Clinical Site
    Budapest, 1083, Hungary
  • Clinical Site
    Budapest, 1134, Hungary
  • Clinical Site
    Gyöngyös, 3200, Hungary
  • Clinical Site
    Guwahati, Assam 781011, India
  • Clinical Site
    Ahmedabad, Gujarat 380013, India
  • Clinical Site
    Junagadh, Gujarat 362001, India
  • Clinical Site
    Vadodara, Gujarat 390021, India
  • Clinical Site
    Mangaluru, Karnataka 575003, India
  • Clinical Site
    Mysore, Karnataka 570001, India
  • Clinical Site
    Kozhikode, Kerala 673009, India
  • Clinical Site
    Aurangabad, Maharashtra 431005, India
  • Clinical Site
    Nagpur, Maharashtra 440010, India
  • Clinical Site
    Nashik, Maharashtra 422005, India
  • Clinical Site
    Nashik, Maharashtra 422101, India
  • Clinical Site
    Ludhiāna, Punjab 141001, India
  • Clinical Site
    Jaipur, Rajasthan 302017, India
  • Clinical Site
    Lucknow, Uttar Pradesh 226003, India
  • Clinical Site
    Varanasi, Uttar Pradesh 221005, India
  • Clinical Site
    Bratislava, 82007, Slovakia
  • Clinical Site
    Košice, 04001, Slovakia
  • Clinical Site
    Rimavská Sobota, 979 01, Slovakia
  • Clinical Site
    Svidník, 089 01, Slovakia
  • Clinical Site
    Vranov Nad Topľou, 09301, Slovakia
  • Clinical Site
    Zlaté Moravce, 953 01, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2024, 30 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 30 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Aug 2, 2021
StartActual
Jul 30, 2021
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 27, 2024
Results first posted
May 2, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04985942
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Jul 30, 2021
Primary completion
Feb 22, 2024
Completion
Feb 27, 2024
Results posted
May 2, 2025
Last update
May 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion